Background
==========

Not all rheumatoid arthritis (RA) patients respond well to the standard infliximab regimen. No clinical or biological factor that would allow one to predict response has yet been identified.

Objective
=========

The aim of the study was to test whether the -308 G/A polymorphism in the promoter of the TNF-α gene and the -1082 G/A polymorphism in the promoter of the IL-10 gene influence response to infliximab therapy in patients with RA.

Methods
=======

We genotyped 85 RA patients for -308TNFalfa polymorphism by PCR and subdivided them into group A (A/A or A/G genotypes) and group B (G/G genotypes). We compared clinical response to infliximab treatment between the two groups after four infusions, using the DAS28 index.

Results
=======

We found that 47.4% of patients in group A and 79.3% of patients in group B had DAS28 index improvement greater than 1.2 (*P*= 0.0075) and that the average DAS28 improvement was 1.12 in group A and 2.08 in group B (*P*= 0.05). IL-10 polymorphism did not allow us to discriminate between good and poor responders.

Conclusion
==========

These data suggest that the -308 A/G and the -308 A/A TNF-α genotypes predict poor response to infliximab therapy in RA. -308TNFalfa genotyping might represent an easy tool with which to predict response to infliximab treatment. Conversely, the IL-10 polymorphism did not appear to be useful.
